Q-omics provides the consensus-scored MRPL10 profile across patient tissues and cancer cell-line models. MRPL10 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MRPL10 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, MRPL10 protein abundance shows 21,418 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where MRPL10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL10 survival associations across molecular data types. MRPL10 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL10 RNA expression–survival associations across cancer types. High MRPL10 expression shows unfavorable associations in ACC, LIHC, PAAD and HNSC, but favorable associations in BRCA and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MRPL10 RNA expression.
This table summarizes MRPL10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL10 shows higher tumor expression in KIRP, HNSC, COAD, KIRC, LIHC and LUAD. The KIRP box plot shows higher MRPL10 RNA expression in tumor versus normal tissue (log2 FC = +1.195, t-test p < 0.001).
This table shows molecular features associated with MRPL10 in patient tissues and cancer cell lines. In patient samples, MRPL10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
